Understanding Patterns of Missingness in Acute Ischemic Stroke Trials: A Secondary Analysis of Pooled Participant-Level Follow-Up Data

Adam De Havenon; Aaron Bangad; Lesli E. Skolarus; Chad M. Aldridge; Robynne G. Braun; John W. Cole; Steven C. Cramer; Arne G. Lindgren; N. Abimbola Sunmonu; Bradford B. Worrall; Keith R. Lohse

doi:10.1161/STROKEAHA.122.042168

Understanding Patterns of Missingness in Acute Ischemic Stroke Trials: A Secondary Analysis of Pooled Participant-Level Follow-Up Data

Adam De Havenon^*, Aaron Bangad, Lesli E. Skolarus, Chad M. Aldridge, Robynne G. Braun, John W. Cole, Steven C. Cramer, Arne G. Lindgren, N. Abimbola Sunmonu, Bradford B. Worrall, Keith R. Lohse

^*Corresponding author for this work

Neurology

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Original language	English (US)
Pages (from-to)	E201-E202
Journal	Stroke
Volume	54
Issue number	5
DOIs	https://doi.org/10.1161/STROKEAHA.122.042168
State	Published - May 1 2023

Funding

Dr de Havenon receives research funding from the National Institutes of Health (NIH), consultant fees from Integra and Novo Nordisk, royalty fees from UpToDate, and equity in TitinKM and Certus. Dr Cramer serves as a consultant for Abbvie, Constant Therapeutics, MicroTransponder, Neurolutions, SanBio, Panaxium, NeuExcell, Elevian, Medtronic, Helius, Omniscient, and TRCare. Dr Lindgren reports personal fees from Bayer, NovoNordisk, Astra Zeneca, and BMS Pfizer. Dr Skolarus reports research funding from NIH and American Heart Association, and employment by University of Michigan and Northwestern. The other authors report no conflicts.

Keywords

albumin
ethnicity
hyperglycemia
ischemic stroke
odds ratio

ASJC Scopus subject areas

Clinical Neurology
Cardiology and Cardiovascular Medicine
Advanced and Specialized Nursing

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1161/STROKEAHA.122.042168

Cite this

De Havenon, A., Bangad, A., Skolarus, L. E., Aldridge, C. M., Braun, R. G., Cole, J. W., Cramer, S. C., Lindgren, A. G., Sunmonu, N. A., Worrall, B. B., & Lohse, K. R. (2023). Understanding Patterns of Missingness in Acute Ischemic Stroke Trials: A Secondary Analysis of Pooled Participant-Level Follow-Up Data. Stroke, 54(5), E201-E202. https://doi.org/10.1161/STROKEAHA.122.042168

@article{d8e0becac97a4f97bf76725559ecf7ab,

title = "Understanding Patterns of Missingness in Acute Ischemic Stroke Trials: A Secondary Analysis of Pooled Participant-Level Follow-Up Data",

keywords = "albumin, ethnicity, hyperglycemia, ischemic stroke, odds ratio",

author = "{De Havenon}, Adam and Aaron Bangad and Skolarus, {Lesli E.} and Aldridge, {Chad M.} and Braun, {Robynne G.} and Cole, {John W.} and Cramer, {Steven C.} and Lindgren, {Arne G.} and Sunmonu, {N. Abimbola} and Worrall, {Bradford B.} and Lohse, {Keith R.}",

note = "Funding Information: Dr de Havenon receives research funding from the National Institutes of Health (NIH), consultant fees from Integra and Novo Nordisk, royalty fees from UpToDate, and equity in TitinKM and Certus. Dr Cramer serves as a consultant for Abbvie, Constant Therapeutics, MicroTransponder, Neurolutions, SanBio, Panaxium, NeuExcell, Elevian, Medtronic, Helius, Omniscient, and TRCare. Dr Lindgren reports personal fees from Bayer, NovoNordisk, Astra Zeneca, and BMS Pfizer. Dr Skolarus reports research funding from NIH and American Heart Association, and employment by University of Michigan and Northwestern. The other authors report no conflicts. ",

year = "2023",

month = may,

day = "1",

doi = "10.1161/STROKEAHA.122.042168",

language = "English (US)",

volume = "54",

pages = "E201--E202",

journal = "Stroke",

issn = "0039-2499",

publisher = "Wolters Kluwer Health",

number = "5",

}

TY - JOUR

T1 - Understanding Patterns of Missingness in Acute Ischemic Stroke Trials

T2 - A Secondary Analysis of Pooled Participant-Level Follow-Up Data

AU - De Havenon, Adam

AU - Bangad, Aaron

AU - Skolarus, Lesli E.

AU - Aldridge, Chad M.

AU - Braun, Robynne G.

AU - Cole, John W.

AU - Cramer, Steven C.

AU - Lindgren, Arne G.

AU - Sunmonu, N. Abimbola

AU - Worrall, Bradford B.

AU - Lohse, Keith R.

N1 - Funding Information: Dr de Havenon receives research funding from the National Institutes of Health (NIH), consultant fees from Integra and Novo Nordisk, royalty fees from UpToDate, and equity in TitinKM and Certus. Dr Cramer serves as a consultant for Abbvie, Constant Therapeutics, MicroTransponder, Neurolutions, SanBio, Panaxium, NeuExcell, Elevian, Medtronic, Helius, Omniscient, and TRCare. Dr Lindgren reports personal fees from Bayer, NovoNordisk, Astra Zeneca, and BMS Pfizer. Dr Skolarus reports research funding from NIH and American Heart Association, and employment by University of Michigan and Northwestern. The other authors report no conflicts.

PY - 2023/5/1

Y1 - 2023/5/1

KW - albumin

KW - ethnicity

KW - hyperglycemia

KW - ischemic stroke

KW - odds ratio

UR - http://www.scopus.com/inward/record.url?scp=85153804121&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85153804121&partnerID=8YFLogxK

U2 - 10.1161/STROKEAHA.122.042168

DO - 10.1161/STROKEAHA.122.042168

M3 - Article

C2 - 36896708

AN - SCOPUS:85153804121

SN - 0039-2499

VL - 54

SP - E201-E202

JO - Stroke

JF - Stroke

IS - 5

ER -

Understanding Patterns of Missingness in Acute Ischemic Stroke Trials: A Secondary Analysis of Pooled Participant-Level Follow-Up Data

Funding

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this